**Patient Name** 0962SP  
**Patient ID** 0962SP  
**Chain** 20000387  
**Age** Not Given  
**DOB** Not Given  
**Gender** Not Given  
**Workorder** 20000387  
**Received** 03/05/2020 11:18

---

**Sample ID** 20000387-001  
**Matrix** Serum or Plasma  
**Patient Name** 0962SP  
**Patient ID** 0962SP  
**Container Type** Clear vial  
**Collect Dt/Tm** Not Given  
**Source** Not Given  
**Approx Vol/Weight** Not Given

---

**Analysis and Comments**

<table>
<thead>
<tr>
<th>Result</th>
<th>Units</th>
<th>Reporting Limit</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>None Detected</td>
<td>ng/mL</td>
<td>0.10</td>
<td></td>
</tr>
</tbody>
</table>

**0962SP Cannabidiol, Serum/Plasma**

Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Cannabidiol

| Synonym(s): | CBD |

Mean peak CBD plasma concentrations at 3-4 hours post-dose with Sativex® at a low dose (5.4 mg of Delta-9 THC and 5.0 mg of Cannabidiol) were 1.6 +/- 0.4 ng/mL and at a high dose (16 mg of Delta-9 THC and 15 mg of Cannabidiol) were 6.7 +/- 2.0 ng/mL.

Following high dose 400 and 800 mg oral synthetic CBD in corn oil administration, mean peak CBD plasma concentrations occurred within 1.5-3 hours post-dose and were 181.2 +/- 39.8 and 221.1 +/- 35.6 ng/mL, respectively.

The ratio of blood to serum or plasma concentration is unknown for this analyte.

Known Interferences: Excessive amounts of oleamide from plastic tubes.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.